FDA rules need tweaking
FDA rules need tweaking The biotech industry is suffering a mini-crisis of confidence that mirrors the larger shocks that have sent Wall Street reeling.
FDA rules need tweaking The biotech industry is suffering a mini-crisis of confidence that mirrors the larger shocks that have sent Wall Street reeling.
deCODED? A new map of the human genome should help both doctors and biologists
Will R&D Make Merck Hot Again? The drug giant gets out of the prescription business and bets it all on science.
Will R&D Make Merck Hot Again? The drug giant gets out of the prescription business and bets it all on science.
Cracking the cancer code Whether a tumor invades the lung or breast is beside the point. Its genetic activity will dictate how to attack it
Report raps drug firms’ ‘post-approval’ studies Drug manufacturers spent $1.5 billion in 2000 to test medicines already approved by the Food and Drug Administration primarily so they could make new marketing claims to sell their products, industry specialists said this week. Critics say the trend inflates health care costs while undercutting the integrity of research.
Report raps drug firms’ ‘post-approval’ studies Drug manufacturers spent $1.5 billion in 2000 to test medicines already approved by the Food and Drug Administration primarily so they could make new marketing claims to sell their products, industry specialists said this week. Critics say the trend inflates health care costs while undercutting the integrity of research.
Of Clones and Clowns A distinguished molecular biologist discusses the “cloning circus” and the damage it is doing to serious research
Legal Circumvention Molecular switches provide a route around existing gene patents
5 Big Drug Companies Face R&D Drought Five of the world’s biggest drug companies do not have any potential billion-dollar drugs in late-stage development, highlighting the industry’s current poor R&D productivity, according to a report released on Wednesday.